Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs include telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome. The company's drug development programs also comprise Sotagliflozin, an orally-delivered small molecule drug candidate that is in Phase III clinical trials to treat type 1 diabetes; and has completed two Phase II clinical trials to treat type 2 diabetes, as well as for the treatment of type 2 diabetes in patients with renal impairment. In addition, it develops LX1033, an orally-delivered small molecule compound for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound to treat autoimmune disease; and LX7101, a topically-delivered small molecule compound for the treatment of glaucoma. Further, the company's development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has license and collaboration agreement with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharma shares rally 48% premarket on positive trial of diabetes treatment http://www.marketwatch.com/story/le...sitive-trial-of-diabetes-treatment-2016-09-09 Shares of Lexicon Pharmaceuticals Inc. LXRX, +23.52% rallied a stunning 48% in premarket trade Friday, after the company reported positive results from a late-stage trial of a treatment for type 1 diabetes. The company said the Phase 3 trial of sotagliflozin met its primary endpoint, showing a statistically significant improvement in blood sugar control in patients with type 1 diabetes on a background of optimized insulin. The improvement was made without an increase in severe hypoglycemia, a serious health challenge in type 1 diabetes. Lexicon is working with Sanofi to develop the compound for use in type 1 and type 2 diabetes. Shares were up 15% in the year through Thursday's close, while the S&P 500 SPX, -0.97% has gained 7%.
$LXRX up 16% on positive news with sotagliflozin - it's T2 diabetes SGLT1/2 inhibitor. Invokana by $JNJ is a SGLT2 inhibitor w/$1.4B in rev
Nice range on this one since last November or so... If it holds, this should be sitting up against resistance right now. Watch for a break-out.
